Safety and Efficacy of Anti-Hepatitis D Virus Antibodies in Patients with Chronic Hepatitis D Infection: The SAMBA-D Study

The primary objective of the SAMBA-D study is to evaluate the safety and efficacy of antibodies targeting hepatitis D in patients with chronic hepatitis D infection. Assessing these parameters is clinically significant for managing viral replication and preventing progressive liver damage. Secondary objectives include the monitoring of clinical outcomes and biological responses associated with the administration of the therapeutic agent.

The sponsor did not provide information regarding the total number of participants. The study population consists of patients diagnosed with chronic hepatitis D. The cohort includes both males and females. Participants are categorized within specific age ranges corresponding to clinical codes 3 and 4.

This Phase 3, randomized, double-blind, controlled trial is designed to evaluate the safety and efficacy of antibodies targeting chronic hepatitis D. The study involves a screening visit to determine eligibility, followed by subsequent follow-up visits to monitor clinical outcomes and safety parameters. The sequence of procedures concludes with an end-of-study visit. The total duration of participant involvement is determined by the established clinical monitoring schedule. Early termination of participation may occur based on predefined protocol criteria or safety concerns.

The assessment of efficacy in this Phase 3 clinical trial involves the evaluation of clinical parameters related to chronic hepatitis D infection. Specific endpoints and methodologies for data collection have not been defined.